Fulgent to Announce Fourth Quarter and Full Year 2025 Financial Results on Friday, February 27, 2026
Fulgent Genetics (NASDAQ:FLGT) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Fulgent Genetics: The Price Has Caught Up To Value, But I Still Like The Stock [Seeking Alpha]
Fulgent Genetics (NASDAQ:FLGT) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Fulgent Genetics to Acquire Bako Diagnostics Assets and StrataDx for $55.5 Million [Los Angeles Times (CA)]